Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma.

Haematologica

Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville; Monash Haematology, Monash Health, Clayton; Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton.

Published: July 2021

Not available.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252923PMC
http://dx.doi.org/10.3324/haematol.2020.265611DOI Listing

Publication Analysis

Top Keywords

genome crispr
4
crispr screening
4
screening identifies
4
identifies top2b
4
top2b potential
4
potential target
4
target imid
4
imid sensitization
4
sensitization multiple
4
multiple myeloma
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!